|
Ancillary Presentations
Please fill out the form below to inquire about having an ancillary presentation at the 2009 Safety Pharmacology Society's Annual Meeting
Ancillary Presentation Form—(PDF)
Elsevier BV
PharmaPendium and EMBASE: On the Road to Further Insights
Wednesday, September 16, 2009
12:30 PM—13:30 PM
Palais des Congrès de Strasbourg, Leicester Room
As the world’s leading publisher of science and health information, Elsevier serves more than 30 million scientists, students, and health and information professionals worldwide. Elsevier is committed to making genuine contributions to science and health communities.
Successful drug development requires thorough and timely documentation of side effects of the drug candidate portfolio. With PharmaPendium and EMBASE, we offer you to learn from both unpublished and published sources to optimize the process of identifying side effects. Searching for essential drug safety information is extremely time-consuming. And, despite your best efforts, you could still find yourself missing critical data. The workshop will take you through a case study showing you how PharmaPendium and EMBASE drive new insights by offering relevant, detailed and comprehensive information on drugs.
Lunch will be served during this workshop.
LAB Research Inc.
How to Screen for Arrhythmias in Safety Pharmacology When More Than 86,400 Beats Are Recorded in One Dog Over 24-Hrs?
Wednesday, September 16, 2009
18:00 PM–20:30 PM
Palais de la Musique et des Congres Strasbourg, (France), Salle Kléber
Telemetry is an essential preclinical tool widely used for continuous monitoring of ECG in safety pharmacology studies. On the flip side, the amount of data generated presents a challenge during analysis and interpretation, particularly for identification of cardiac arrhythmias. ECG analysis softwares are evolving at an increasing pace but detection features are mostly focused on normal complexes and the data excluded, albeit limited (<5%), could include artifacts but also arrhythmias. Leading experts Hugo Vargas, Jean-Pierre Valentin and Simon Authier will present strategies to screen ECG data for the presence of cardiac arrhythmias. The session will be followed by an informal round table with attendees. Refreshments and hors d’oeuvre will be served.
Ellegaard Göttingen Minipigs
The Göttingen Minipig in Cardiovascular Safety Pharmacology
Wednesday, September 16, 2009
18:00 PM–21:00 PM
Hilton Strasbourg, Room: Neptune
The Göttingen Minipig has been used in biomedical research since the late nineteen sixties and in toxicology for almost three decades. During the past ten years its use in cardiovascular safety pharmacology has steadily increased. Much has been learned thus far within this field, yet much remains to be investigated.
This session presents findings of a Consortia Collaboration probing the use of minipigs in cardiovascular safety pharmacology, focusing on data obtained from telemetry studies.
Data from participant companies will be presented and discussed, and there will be ample opportunity to engage the speakers in an open and relaxed atmosphere.
Programme:
Refreshments and canapés will be served from 18:00, and after the presentations.
- 19:00: Welcome
Chair: Stephane Milano, MDS Pharma Services
- 19:00–19:05: The Project—Past, Present, Future
Niels-Christian Ganderup, Ellegaard Göttingen Minipigs
- 19:05–19:15: Dofetilide—cross company reference compound
Stephane Milano, MDS Pharma Services & Michael Markert, Boehringer Ingelheim
- 19:15–19:25: Propranolol
Michael Markert, Boehringer Ingelheim
- 19:25–19:35: Sparfloxacin and Isoproterenol
Stephane Milano, MDS Pharma Services
- 19:35–19:45: Sotalol and Astemizole
Guillaume Froget, CIT
- 19:45–19:55: Combining respiratory and CV parameters in the Göttingen Minipig following inhalation dosing
Ken Meecham, Huntingdon LS
- 19:55–20:05: The anaesthetized Göttingen Minipig in cardiovascular safety pharmacology
Christiane Praechter, Nycomed
- 20:05–20:10: Concluding remarks and adjourn
Stephane Milano, MDS Pharma Services
emka TECHNOLOGIES
Advances in Non-Invasive and Invasive Telemetry
Thursday, September 17, 2009
12:30 PM–13:30 PM
Palais des Congrès de Strasbourg, Amphithéâtre Oberlin
Advances in non-invasive and invasive telemetry:
- New physiological parameters
- Rechargeable invasive telemetry from an open system
- Large study organization
- Enhanced data management
Non-invasive telemetry makes it possible to measure not only ecg, activity, temperature but also respiration and blood pressure. New methods are now available to analyze respiration data from a multi-belt RIP device, as well as the signal from a non-invasive blood pressure device.
Invasive telemetry devices have recently become available that allow in-situ battery recharge, very limited refurbishment costs and group housing—all from a fully open system which connects to any existing software.
Large studies involving dozens of subjects can now be organized, recorded and processed within a single system, and run from single or multiple local or distant computers. Tools also allow extensive post-processing as well as direct links to an existing LIMS.
Cellular Dynamics International
Detecting QT Perturbation: The Advantages of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Multivariate Analysis, and the Value of a Reference Database
 
Thursday, September 17, 2009
12:30 PM–14:00 PM
Palais des Congrès de Strasbourg, Room: Kleber (ground floor)
Human induced pluripotent stem (iPS) cell-derived cardiomyocytes are a human-based cardiomyocyte model that expresses the relevant complement of proteins, recapitulates in vivo function, and thus provides an excellent system for in vitro pharmacological assessments. When cultured on multi-electrode arrays, the electrical activity of the cardiomyocytes can be monitored as an extracellular field potential; this signal is thus a direct marker for the cardiomyocyte action potential and underlying ion channel activity. As such, drug-induced changes in this complex waveform reflect the altered activity of the ion channels mediating the cardiac action potential.
Multivariate analysis of the cardiomyocyte MEA field potential is a developing technology with the potential to provide mechanistic detail of drug effects on cardiac electrical activity.
This workshop will highlight CDI’s human iPS-derived cardiomyocytes, VivoMedica’s multivariate analysis of MEA field potential recordings, and the use of this system for assessing potential QT perturbation.
Please register on CDI’s Web site.
Lunch will be served during this workshop.
Data Sciences International
New Applications of Telemetric and Physiological Monitoring in Pharmacology and Safety Pharmacology
Thursday, September 17, 2009
18:30 PM–19:30 PM
Palais de la Musique et des Congres Strasbourg, (France), Salle Tivoli
Cordially invites you to attend our 25th Anniversary Celebration. A Unique Educational (and Entertaining) Celebration Featuring DSI’s annual scientific Data Blast Celebration!
Live presentations will include brief overviews of the newest safety pharmacology applications using wired and wireless telemetry with automated analysis to monitor and analyze physiological data. Twenty five short presentations will focus on the most recent current applications and new method advances in Cardiovascular, CNS, and Respiratory safety pharmacology data assessment. This is a unique opportunity to meet and talk with your peers about their recent research in a relaxed and informal setting.
Celebratory Regional Refreshments and Beverages served.
| 
General Information 
